Precision Medicine in Oncology®

Maher Albitar, MD, discusses the unmet needs with genomic testing that served as the impetus to start GTC, the process of becoming a partner with the organization, and the importance of genomic profiling for all patients with cancer.

Melissa L. Johnson, MD, discusses the potential utility of TROP2 as a therapeutic target for all-comers with solid tumor malignancies.

The ATR inhibitor RP-3500 demonstrated a manageable safety profile and promising early antitumor efficacy in patients whose tumors harbor select genomic alterations when administered at doses of 100 mg or more.

The FDA has approved the VENTANA PD-L1 assay to assist in identifying which adult patients with stage II to IIIA non–small cell lung cancer whose tumors have PD-L1 expression on 1% or more of tumor cells are eligible to receive adjuvant atezolizumab following surgery and platinum-based chemotherapy.

The FDA has approved the Ki-67 IHC MIB-1 pharmDx test to assist in determining which patients with early breast cancer who are at high risk of disease recurrence might benefit from adjuvant treatment with abemaciclib plus endocrine therapy.

Dr. Gordan discusses the advantages of in-house genomic testing, the transition from external to internal sequencing, and the anticipated effects of the move.

Patritumab deruxtecan, a novel antibody-drug conjugate, is emerging as a promising HER3-directed therapy in patients with non–small cell lung cancer and perhaps other solid malignancies.

Investigators have expanded the scientific understanding of cancer in the adolescent young adult patient population over the past decade. However, unmet needs remain in establishing treatment standards, addressing unique survivorship challenges, and providing a framework for patients to reference as they navigate their cancer journey.

The sustainability of next-generation sequencing will be dependent on the implementation of thorough informatics and infrastructure that can support the integration of genomic results into electronic medical records.

Dr. Patel discusses the role of biomarker testing in lung cancer, the FDA approvals of amivantamab and mobocertinib in EGFR exon 20 insertion–positive NSCLC, and future research directions in this subset of lung cancer.

Dr. Scott and Dr. Torres-Roca discuss their research of a pooled retrospective analysis exploring genomic-adjusted radiation dose–based radiation therapy in solid tumors and what using genomics to guide radiation dosing decisions could mean for oncology practices.

Andre H. Goy, MD, discusses the importance of refined decision making with precision medicine.

John L. Marshall, MD, discusses the importance of molecular profiling when utilizing precision medicine.

Benjamin P. Levy, MD, discusses potential strategies to overcome resistance to osimertinib in EGFR-mutant non–small cell lung cancer. 

Clinical limit of detection may be a reasonable metric for evaluating cell-free DNA for multi-cancer early detection.

Current approaches to precision medicine in oncology have been fruitful, but require better integration and utilization of available resources to inform sustainable and effective drug development and clinical care, according to Andre Goy, MD.

Dr. Neel discusses the momentum of molecularly-driven research and treatment strategies in oncology, the continuation of current research trends, and potential future directions throughout the field.

The FDA has granted premarket approval to the Oncomine Dx Target Test for use as a companion diagnostic to identify patients with non–small cell lung cancer whose tumors harbor EGFR exon 20 insertion mutations who may be eligible to receive the newly approved small molecule TKI mobocertinib.

Mobocertinib plus ado-trastuzumab emtansine demonstrated inhibitory effects in HER2 exon 20 insertion–mutated lung cancer cell lines.

The European Association of Neuro-Oncology and ESMO have released clinical practice guidelines, which provide management recommendations for the diagnosis, treatment, and follow-up of patients with solid tumor brain metastases.

Genomic-adjusted radiation dose demonstrated a significant association with time to first recurrence and overall survival in patients with certain solid tumors who had been treated with radiation therapy, indicating that genomics should be used to guide radiation dosing decisions.

Javier Torres-Roca, MD, discusses optimizing radiation therapy with genomic-adjusted radiation dose–based radiotherapy dosing in oncology.

Jacob G. Scott, MD, DPhil, discusses the incorporation of genomic-adjusted radiation dose–based radiotherapy dosing in oncology.

The rapid development of novel agents directed at anaplastic lymphoma kinase gene fusions has emerged as one of the success stories of the targeted therapy era in non–small cell lung cancer

Jacob G. Scott, MD, DPhil, discusses the rationale to evaluate genomic-adjusted radiation dose–based radiotherapy dosing in oncology.